Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximab

Jürgen Braun, Désirée Van Der Heijde, Mittie K. Doyle, Chenglong Han, Atulya (Atul) Deodhar, Robert Inman, Kurt De Vlam, Gerd R. Burmester, Filip Van Den Bosch, Stephen Xu, Sudha Visvanathan, Mahboob U. Rahman

Research output: Contribution to journalArticle

16 Scopus citations

Abstract

Objective. Anemia is a common complication in patients with inflammatory diseases such as ankylosing spondylitis (AS). This post hoc analysis of a large, randomized, placebo-controlled trial examined the effect of infliximab on hemoglobin levels, physical function, and fatigue in patients with AS. Methods. Patients received infliximab 5 mg/kg (n = 188) or placebo (n = 68) at weeks 0, 2, 6, 12, and 18. Hemoglobin, interleukin-6 (IL-6), and C-reactive protein (CRP) levels, fatigue (visual analog scale [VAS]), physical function (Bath Ankylosing Spondylitis Functional Index [BASFI]), and disease activity were evaluated at baseline and week 24. Anemia was defined as a hemoglobin level

Original languageEnglish (US)
Pages (from-to)1032-1036
Number of pages5
JournalArthritis Care and Research
Volume61
Issue number8
DOIs
StatePublished - Aug 15 2009

    Fingerprint

ASJC Scopus subject areas

  • Rheumatology

Cite this

Braun, J., Van Der Heijde, D., Doyle, M. K., Han, C., Deodhar, A. A., Inman, R., De Vlam, K., Burmester, G. R., Van Den Bosch, F., Xu, S., Visvanathan, S., & Rahman, M. U. (2009). Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximab. Arthritis Care and Research, 61(8), 1032-1036. https://doi.org/10.1002/art.24865